Study: Intracranial bleeding risk lower in rivaroxaban users

02/3/2012 | Family Practice News

A sub-analysis of the ROCKET-AF trial showed that patients with atrial fibrillation who took the new anticoagulant rivaroxaban to prevent stroke were 40% less likely to have intracranial hemorrhages than warfarin users. Researchers also found that adding clopidogrel to either warfarin or rivaroxaban increased the risk of intracranial bleeding by 250% compared with clopidogrel or warfarin alone.

View Full Article in:

Family Practice News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA